BACKGROUND: DSP cardiomyopathy is a distinct subset of arrhythmogenic cardiomyopathy, reported primarily in adults, that has predominantly left ventricular involvement and features of myocarditis. Clinical characteristics, risk stratification, and management of pediatric patients with DSP variants are not well known. We sought to identify phenotypic features and prognosis of pediatric patients with DSP pathogenic or likely pathogenic variants. METHODS: Multicenter, retrospective study of patients <21 years of age with DSP variants from 6 tertiary pediatric hospitals. RESULTS: Thirty-four patients, including 10 probands with clinical disease and 24 genotype-positive phenotype-negative patients, were included in the study. The majority of probands were initially diagnosed with myocarditis (50%) and had biventricular (60%) or left ventricular predominant (40%) disease. Chest pain was the most common symptom at presentation (30%), and all had troponin elevation. Probands with homozygous or compound heterozygous DSP variants were likely to present at an early age (<13 years) with symptoms of heart failure, severe biventricular involvement, and dermatologic abnormalities. Low-voltage QRS was the most prominent ECG abnormality. Of those who underwent implantable cardioverter defibrillator implantation, 50% received appropriate implantable cardioverter defibrillator therapy and were found to have significant biventricular involvement in addition to severe left ventricular dysfunction with an ejection fraction <35%. CONCLUSIONS: DSP cardiomyopathy in children and adolescents has varied phenotypic manifestations based on age and genotype and often can be diagnosed as myocarditis. Severe left ventricular dysfunction and biventricular involvement may be associated with a higher likelihood of malignant ventricular tachyarrhythmia.
Congenital long QT syndrome (LQTS) is a group of heritable conditions that are associated with cardiac repolarization abnormalities characterized by QT prolongation on electrocardiogram and the risk of life-threatening arrhythmias. The prenatal detection of LQTS presents significant challenges for clinicians, and a multidisciplinary approach is required for optimal prenatal and postnatal management. In this comprehensive literature review, we describe strategies for the fetal diagnosis of LQTS with variable initial presentation, genetic testing in suspected fetal LQTS, the utility of fetal magnetocardiography as an additional diagnostic tool, prenatal management, and postnatal treatment. We focus on a multidisciplinary team approach including fetal cardiology, adult and pediatric electrophysiology, neonatology, maternal–fetal medicine, and genetic counselors, all playing vital roles in the comprehensive prenatal management and orchestration of postnatal treatment to optimize neonatal outcomes.
Congenital long QT syndrome (LQTS) is a group of heritable conditions that are associated with cardiac repolarization abnormality characterized by QT prolongation on ECG and risk of life‐threatening arrhythmias. Prenatal detection of LQTS presents many challenges for clinicians and a multidisciplinary approach is needed for optimal prenatal and postnatal management. We describe five cases of fetal diagnosis of LQTS with variable initial presentation, diagnostic strategies, and management approaches. A multidisciplinary team approach including fetal cardiologist, adult and pediatric electrophysiologists, medical physicists, neonatologists, maternal–fetal medicine specialists, fetal cardiac nurse coordinators, and genetic counselors allowed for comprehensive prenatal management and well‐planned postnatal treatment to optimize neonatal and maternal outcomes.
Genetic counselors (GCs) educate patients about the benefits, risks, and limitations of genetic testing. The regulatory environment governing the use of genetic data in life insurance is not uniform internationally or within the United States (US). This multinational survey assessed how cardiovascular GCs incorporate the topic of life insurance (LI) into patient discussions. An online survey was distributed to GCs currently providing care to patients with non‐syndromic cardiovascular disease. Brief clinical scenarios were included to avoid participants considering ambiguous or marginal phenotypes. Respondents were 121 cardiovascular GCs from five countries. Patient phenotype was the strongest indicator of whether GCs engaged in LI discussion. For phenotype‐negative pediatric and adult patient scenarios, 62% and 74% of participants would discuss LI. For phenotype‐positive pediatric and adult patient scenarios, 29% and 39% of participants would discuss LI. Non‐U.S. participants were more likely to discuss LI with phenotype‐positive patients than U.S. participants (61% vs. 33%, p = 0.005). Participants seeing primarily adult patients were more likely to discuss LI than those seeing primarily pediatric patients, for both pediatric (44% vs. 12%, p = 0.003) and adult phenotype‐positive scenarios (46% vs. 17%, p = 0.008). Most participants would discuss LI with family variant testing (91%). Many participants reported patients declining genetic testing due to fear of genetic discrimination (77%) and 21% reported patients who were denied LI due to a genetic test result. Insufficient time was an important reported reason to not discuss LI (31%). Most participants reported learning about LI considerations in graduate education and reported confidence in their knowledge and ability to learn about related laws. Patient phenotype was the primary driver of whether cardiovascular GCs discussed life insurance implications of genetic testing with their patients, regardless of the age of the patient or the nationality of the genetic counselor. This study is the first to assess this nuanced aspect of cardiovascular genetic counseling and may support GC practice decisions and education.